December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
1 citations
,
June 2011 in “Journal of Dermatological Case Reports” Shaving and applying erythromycin cream and clotrimazole powder effectively treated trichomycosis axillaris.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
November 2025 in “Journal of Multidisciplinary Healthcare” Combining fire needle therapy with doxycycline improves severe acne more than doxycycline alone.
34 citations
,
June 2022 in “Viruses” Certain plant compounds can help prevent and treat a virus in pigs.
10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes”
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
14 citations
,
January 2011 in “Urologia Internationalis” Finasteride may help prevent chronic bacterial prostatitis, with better results when combined with antibiotics.
40 citations
,
August 2018 in “Journal of the American Academy of Dermatology” Clindamycin and rifampicin are the most effective treatments for folliculitis decalvans, but more research is needed.
January 2026 in “Journal of Advanced Research” Bacillus sp. TC5 products help hair regrowth and improve skin drug absorption.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
1 citations
,
February 2025 in “Notulae Scientia Biologicae” Optimized emulgels with Levofloxacin effectively treat eye infections with prolonged drug release and safety.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
1 citations
,
January 2024 in “Surgical & Cosmetic Dermatology” Botulinum toxin A helped a patient recover from dissecting folliculitis when antibiotics failed.
1 citations
,
May 2022 in “Голова и шея.” The collagen sponge with lincomycin heals tooth sockets faster and reduces infection better than iodoform gauze.
1 citations
,
April 2023 in “International Journal of Molecular Sciences” Botryococcus terribilis Ethanol Extract may reduce inflammation by changing gene expression in cells.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.